Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Dietlein

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Molecular Imaging and Biology|October 2, 2020
[<sup>18</sup>F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate CancerFelix Dietlein, Peter Mueller, Carsten Kobe, et al.
Nature Genetics|February 5, 2020
Identification of cancer driver genes based on nucleotide contextFelix Dietlein, Donate Weghorn, Amaro Taylor-Weiner, et al.
Molecular Imaging and Biology|August 9, 2021
Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate CancerSergio Muñoz Vázquez, Heike Endepols, Thomas Fischer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
An <sup>89</sup>Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer PatientsFelix Dietlein, Carsten Kobe, Sergio Muñoz Vázquez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 21, 2019
An <sup>18</sup>F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with <sup>18</sup>F-JK-PSMA-7 During the First Year of ApplicationFelix Dietlein, Melanie Hohberg, Carsten Kobe, et al.
EJNMMI Research|January 10, 2025
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapyJan Heilinger, Katrin Sabine Roth, Henning Weis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2016
PSA-Stratified Performance of <sup>18</sup>F- and <sup>68</sup>Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate CancerFelix Dietlein, Carsten Kobe, Stephan Neubauer, et al.
Nature Communications|August 27, 2016
The tumour suppressor CYLD regulates the p53 DNA damage responseVanesa Fernández-Majada, Patrick-Simon Welz, Maria A Ermolaeva, et al.
Cancer Discovery|February 22, 2014
A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDCFelix Dietlein, Lisa Thelen, Mladen Jokic, et al.
International Journal of Molecular Sciences|October 16, 2024
Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [<sup>131</sup>I]-Iodine-ERIC1 in Neuroblastoma-Bearing MiceThomas Fischer, Felix Dietlein, Detlev Bongartz, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Molecular Imaging and Biology|October 2, 2020
[<sup>18</sup>F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate CancerFelix Dietlein, Peter Mueller, Carsten Kobe, et al.
Nature Genetics|February 5, 2020
Identification of cancer driver genes based on nucleotide contextFelix Dietlein, Donate Weghorn, Amaro Taylor-Weiner, et al.
Molecular Imaging and Biology|August 9, 2021
Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate CancerSergio Muñoz Vázquez, Heike Endepols, Thomas Fischer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
An <sup>89</sup>Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer PatientsFelix Dietlein, Carsten Kobe, Sergio Muñoz Vázquez, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 21, 2019
An <sup>18</sup>F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with <sup>18</sup>F-JK-PSMA-7 During the First Year of ApplicationFelix Dietlein, Melanie Hohberg, Carsten Kobe, et al.
EJNMMI Research|January 10, 2025
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapyJan Heilinger, Katrin Sabine Roth, Henning Weis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 3, 2016
PSA-Stratified Performance of <sup>18</sup>F- and <sup>68</sup>Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate CancerFelix Dietlein, Carsten Kobe, Stephan Neubauer, et al.
Nature Communications|August 27, 2016
The tumour suppressor CYLD regulates the p53 DNA damage responseVanesa Fernández-Majada, Patrick-Simon Welz, Maria A Ermolaeva, et al.
Cancer Discovery|February 22, 2014
A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDCFelix Dietlein, Lisa Thelen, Mladen Jokic, et al.
International Journal of Molecular Sciences|October 16, 2024
Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [<sup>131</sup>I]-Iodine-ERIC1 in Neuroblastoma-Bearing MiceThomas Fischer, Felix Dietlein, Detlev Bongartz, et al.
Pageof 5